Get the Stockscreener App
1.32
12.82%
0.15
Pre-market:
1.46
0.14
+10.61%
Ocugen Inc stock is traded at $1.32, with a volume of 8.84M.
It is up +12.82% in the last 24 hours and up +25.71% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.17
Open:
$1.17
24h Volume:
8.84M
Relative Volume:
2.10
Market Cap:
$385.84M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-4.8889
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
+26.92%
1M Performance:
+25.71%
6M Performance:
+130.53%
1Y Performance:
+17.86%
1-Day Range:
$1.17
$1.33
1-Week Range:
$1.03
$1.33
52-Week Range:
$0.515
$1.33
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.32 | 365.40M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Setup Watch: Can Ocugen Inc be recession proofStop Loss & Precise Buy Zone Identification - خودرو بانک
Panic Selling: What is the next catalyst for Ocugen IncWeekly Market Report & High Conviction Investment Ideas - خودرو بانک
Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN
Aug Intraday: Is Ocugen Inc forming a double bottomJuly 2025 Sector Moves & Technical Buy Zone Confirmation - خودرو بانک
Gains Recap: What is the next catalyst for Mattel IncDay Trade & Reliable Price Action Trade Plans - خودرو بانک
Ocugen, Kwangdong complete licensing agreement for OCU400 gene therapy in Korea - Modern Retina
Why Ocugen (OCGN) Is Up 16.5% After Licensing OCU400 Gene Therapy Rights to Kwangdong - au.finance.yahoo.com
Ocugen Signs Exclusive License Agreement with Kwangdong - TipRanks
Ideas Watch: Is Ocugen Inc undervalued by DCF analysisWeekly Volume Report & Expert Curated Trade Setup Alerts - خودرو بانک
Published on: 2025-09-16 04:47:37 - خودرو بانک
Big Money Moves: Is Ocugen Inc showing insider buyingQuarterly Performance Summary & Weekly Momentum Stock Picks - خودرو بانک
Why Ocugen Stock Zoomed 12% Higher Today - The Globe and Mail
Why Ocugen Stock Zoomed 12% Higher Today - The Motley Fool
Ocugen Shares Are Trading Higher Monday: What's Going On? - Benzinga
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen
Ocugen and Kwangdong complete licensing agreement for OCU400 gene therapy in Korea - Ophthalmology Times
Ocugen (OCGN) Secures Licensing Deal with Kwangdong for Gene Therapy in Korea - GuruFocus
Ocugen, Inc. Announces Licensing Agreement with Kwangdong Pharmaceutical for OCU400, Potentially Worth Up to $187.5 Million - Quiver Quantitative
$180M+ Sales Milestone Deal: Ocugen Partners with Korean Pharma Giant for Breakthrough Eye Gene Therapy - Stock Titan
Ocugen CEO to Speak at Investor Conferences in New York and Munich - MSN
756,926 Shares in Ocugen, Inc. $OCGN Bought by Nuveen LLC - MarketBeat
Advanced analytics toolkit walkthrough for Ocugen Inc.Product Launch & Technical Buy Zone Confirmation - Newser
Is Ocugen Inc. forming bullish engulfing patterns2025 Winners & Losers & Risk Adjusted Swing Trade Ideas - خودرو بانک
What makes Ocugen Inc. stock attractive todayEarnings Growth Report & Daily Oversold Stock Bounce Ideas - خودرو بانک
Ocugen Enters Subscription Agreement with Carisma Therapeutics - MSN
Real time alert setup for Ocugen Inc. performanceTrade Entry Summary & Daily Entry Point Alerts - Newser
What’s the MACD signal for Ocugen Inc.July 2025 Rallies & Low Risk Growth Stock Ideas - خودرو بانک
Can Ocugen Inc. hit a new high this monthWeekly Loss Report & Reliable Intraday Trade Plans - Newser
Is Ocugen Inc. forming a double bottom2025 Market Outlook & AI Forecast for Swing Trade Picks - خودرو بانک
Has Ocugen Inc. found a price floorJuly 2025 Breakouts & High Yield Equity Trading Tips - Newser
How to use Fibonacci retracement on Ocugen Inc.Weekly Stock Recap & Weekly Setup with ROI Potential - Newser
Is Ocugen Inc. building a consolidation baseRate Cut & Weekly High Potential Stock Alerts - Newser
Will Ocugen Inc. continue its uptrend2025 Volume Leaders & Expert Curated Trade Ideas - Newser
Is Ocugen Inc. forming a bottoming baseDip Buying & Stock Portfolio Risk Management - Newser
What’s next for Ocugen Inc. stock priceMarket Risk Analysis & Expert-Curated Trade Recommendations - Newser
What is the next catalyst for Ocugen Inc.July 2025 Institutional & Stepwise Trade Execution Plans - خودرو بانک
Visual trend scoring systems applied to Ocugen Inc.2025 Market Outlook & Verified Short-Term Trading Plans - Newser
Technical analysis overview for Ocugen Inc. stockQuarterly Portfolio Report & Stepwise Trade Signal Implementation - Newser
Will Ocugen Inc. benefit from rising consumer demandQuarterly Profit Report & Daily Technical Forecast Reports - خودرو بانک
Does Ocugen Inc. have high return on assetsOptions Play & AI Forecasted Stock Moves - khodrobank.com
What is Ocugen Inc. s 5 year growth outlookJuly 2025 WrapUp & Free Low Drawdown Momentum Trade Ideas - خودرو بانک
Is Ocugen Inc. stock a smart retirement pickWeekly Trade Summary & Reliable Price Action Trade Plans - خودرو بانک
What does recent volatility data suggest for Ocugen Inc.Trade Performance Summary & Consistent Profit Focused Trading Strategies - Newser
Pattern recognition hints at Ocugen Inc. upsideJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - Newser
Volatility clustering patterns for Ocugen Inc.2025 Bull vs Bear & Stock Portfolio Risk Control - Newser
Are Bears Losing Grip on Ocugen Inc. getLinesFromResByArray error: size == 0 - news-j.co.kr
Buyout Rumor: Is Ocugen Inc. stock overvalued or fairly pricedMarket Trend Review & Safe Entry Zone Tips - خودرو بانک
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):